Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Phathom Pharmaceuticals Inc PHAT

Healthcare
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are... see more

Recent & Breaking News (NDAQ:PHAT)

Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)

GlobeNewswire December 14, 2020

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

GlobeNewswire November 30, 2020

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

GlobeNewswire November 27, 2020

Phathom Pharmaceuticals to Host Virtual Investor Day

GlobeNewswire November 19, 2020

Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

GlobeNewswire November 13, 2020

Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials

GlobeNewswire November 10, 2020

Arcutis Announces Appointment of Terrie Curran to Board of Directors

GlobeNewswire November 4, 2020

Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference

GlobeNewswire September 9, 2020

Phathom Pharmaceuticals Reports Second Quarter 2020 Results

GlobeNewswire August 6, 2020

Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer

GlobeNewswire July 13, 2020

Phathom Pharmaceuticals Provides Clinical Trial Status Update

GlobeNewswire June 15, 2020

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire May 28, 2020

Phathom Pharmaceuticals Reports First Quarter 2020 Results

GlobeNewswire May 12, 2020

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 9, 2020

Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates

GlobeNewswire March 19, 2020

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

GlobeNewswire February 25, 2020

Frazier Healthcare Partners Closes Oversubscribed $617 Million Life Sciences Fund

PR Newswire January 16, 2020

Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer

Business Wire January 6, 2020

Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection

Business Wire December 23, 2019

Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition

Business Wire December 2, 2019